Drug intelligence / Profile preview

CL-H2T

Development stage: Preclinical
Lead developer: Charleston Laboratories
Modality: Small Molecules

Overview

CL-H2T is a **preclinical** central nervous system drug candidate from Charleston Laboratories. It is publicly described as a novel formulation that combines an undisclosed compound with an antiemetic; the individual active ingredients, molecular targets, and pharmacology have not been disclosed. Public pipeline and drug-database records associate the program with migraine disorders and vomiting. ([charlestonlabs.com](https://charlestonlabs.com/pipeline/central-nervous-system/))

Beyond the preview

Go deeper on CL-H2T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-H2T.

Explore the full profile